ScanScor NDAPR Events
Total Events
601
Alerts
190
Active
460
Partial / Realized
107 / 3
Broken / Expired
29 / 0
YES_UP / YES_DOWN / NONE
167 / 24 / 410
| Created | Ticker | Status | Direction | Window / Target | Catalyst | Reason / Rationale |
|---|---|---|---|---|---|---|
|
2026-06-05 12:52:20
Event ID 679
Report 1615
|
NRXP
MODIFIED
|
ACTIVE
Parse: PARSED
|
NONE
Breakout: 34%
DBR: {"expected_direction":"PARTIAL_DELAY","directional_odds_up_down":"55_45","downside_risk":"HIGH","potential_high":"4.40","potential_low":"2.40","dbr_action":"REVISE"}
|
2026-06-22 to 2026-08-07 Target: $4.40 |
Summer 2026 FDA labeling concurrence and potential GDUFA approval for preservative-free ketamine, now offset by fresh dilution despite supportive ketamine efficacy messaging. |
Primary FDA catalyst still pending; recent news shows catalyst progress but no approval outcome. Catalyst progress. Supportive ketamine positioning is outweighed by completed public offering dilution, reducing odds of hitting the prior target before the FDA decision. |
|
2026-06-05 12:30:23
Event ID 678
Report 1618
|
MBRX
MODIFIED
|
ACTIVE
ALERT
Parse: PARSED
|
YES_UP
Breakout: 45%
DBR: {"expected_direction":"UP","directional_odds_up_down":"58_42","downside_risk":"HIGH","potential_high":"5.75","potential_low":"1.60","dbr_action":"REVISE"}
|
2026-05-13 to 2026-07-15 Target: $5.75 |
Mid-2026 MIRACLE interim unblinding remains primary catalyst; commercial-interest survey modestly strengthens pre-readout narrative. |
Primary MIRACLE interim unblinding still pending Catalyst progress. Physician and payer interest supports upside sentiment, but the thesis still depends on the pending MIRACLE unblinding. |
|
2026-06-04 21:13:52
Event ID 677
Report 1615
|
NRXP
MODIFIED
|
ACTIVE
ALERT
Parse: PARSED
|
YES_DOWN
Breakout: 34%
DBR: {"expected_direction":"PARTIAL_DELAY","directional_odds_up_down":"45_55","downside_risk":"HIGH","potential_high":"4.40","potential_low":"2.60","dbr_action":"REVISE"}
|
2026-06-22 to 2026-08-07 Target: $4.40 |
Summer 2026 FDA labeling concurrence and potential preservative-free ketamine approval, now offset by completed dilutive financing that improves runway but caps upside. |
Primary FDA catalyst still pending; financing changes risk-reward but does not resolve thesis Catalyst progress. The FDA thesis remains pending, but the closed discounted equity raise adds dilution and likely reduces odds of hitting the prior target. |
|
2026-06-04 13:46:36
Event ID 676
Report 1665
|
MAIA
MODIFIED
|
BROKEN
ALERT
Parse: PARSED
|
YES_UP
Breakout: 32%
DBR: {"expected_direction":"PARTIAL_DELAY","directional_odds_up_down":"60_40","downside_risk":"HIGH","potential_high":"2.40","potential_low":"0.95","dbr_action":"REVISE"}
|
2026-12-15 to 2027-03-31 Target: $2.40 |
THIO-104 enrollment progress toward 100 patients and path to 2027 interim survival analysis, with possible THIO-101 U.S. expansion updates |
News indicated primary catalyst was delayed more than 30 days Catalyst progress. Strong Phase 3 enrollment supports execution, but expected interim survival analysis now points to 2027, beyond the original window. |
|
2026-06-04 12:32:34
Event ID 675
Report 1618
|
MBRX
NO_CHANGE
|
ACTIVE
Parse: PARSED
|
NONE
Breakout:
DBR: {"expected_direction":"UP","directional_odds_up_down":"60_40","downside_risk":"HIGH","potential_high":"5.50","potential_low":"1.60","dbr_action":"REAFFIRM"}
|
Interim MIRACLE unblinding remains pending and on track for June 2026 Catalyst progress. CEO commentary reiterates enrollment milestone and June unblinding timing, but no unblinded MIRACLE efficacy data or thesis-defining outcome was released. |
||
|
2026-06-04 12:03:27
Event ID 674
Report 1621
|
NXTC
MODIFIED
|
PARTIALLY_REALIZED
ALERT
Parse: PARSED
|
YES_UP
Breakout: 24%
DBR: {"expected_direction":"PARTIAL_DELAY","directional_odds_up_down":"45_55","downside_risk":"HIGH","potential_high":"12.50","potential_low":"7.00","dbr_action":"REVISE"}
|
2026-06-04 to 2026-06-30 Target: $12.50 |
Post-ASCO SIM0505 data digestion and dose-optimization follow-through |
ASCO SIM0505 data were presented, but full value realization remains unproven Catalyst hit. ASCO SIM0505 data arrived and dose optimization already started, but replay-only news suggests Catalyst progress with weaker remaining upside than originally forecast. |
|
2026-06-04 12:00:24
Event ID 673
Report 1583
|
SNES
MODIFIED
|
PARTIALLY_REALIZED
ALERT
Parse: PARSED
|
YES_UP
Breakout: 55%
DBR: {"expected_direction":"UP","directional_odds_up_down":"60_40","downside_risk":"HIGH","potential_high":"3.00","potential_low":"1.30","dbr_action":"REVISE"}
|
2026-06-04 to 2026-07-31 Target: $3.00 |
Additional international distribution and approval traction |
International expansion catalyst progress confirmed Catalyst progress. Bermuda distribution supports the thesis, but small-market expansion alone does not fully justify the original 3.50 target by July. |
|
2026-06-03 13:46:09
Event ID 672
Report 1665
|
MAIA
NO_CHANGE
|
PARTIALLY_REALIZED
ALERT
Parse: PARSED
|
YES_UP
Breakout:
DBR: {"expected_direction":"UP","directional_odds_up_down":"62_38","downside_risk":"HIGH","potential_high":"2.60","potential_low":"0.95","dbr_action":"REAFFIRM"}
|
Supportive FDA-cleared Phase 2 expansion progress, but primary Phase 3 update remains pending Catalyst progress. FDA-cleared U.S. Phase 2 enrollment and manufacturing updates strengthen execution credibility, but the thesis-defining Phase 3 update has not occurred. |
||
|
2026-06-03 13:02:37
Event ID 671
Report 1620
|
CVKD
MODIFIED
|
ACTIVE
Parse: PARSED
|
NONE
Breakout: 34%
DBR: {"expected_direction":"PARTIAL_DELAY","directional_odds_up_down":"55_45","downside_risk":"HIGH","potential_high":"7.50","potential_low":"3.50","dbr_action":"REVISE"}
|
2026-06-03 to 2026-06-30 Target: $7.50 |
Formal Phase 3 protocol finalization or initiation timing update for CAD-1005 after BIO 2026 partnering outreach |
Phase 3-defining catalyst still pending; BIO participation only signals readiness and partnering outreach Catalyst progress. BIO attendance and “P3-ready” language support the thesis, but the actual protocol finalization or start-timing announcement has not yet occurred. |
|
2026-06-03 12:30:43
Event ID 670
Report 1633
|
INAB
MODIFIED
|
PARTIALLY_REALIZED
Parse: PARSED
|
NONE
Breakout: 46%
DBR: {"expected_direction":"UP","directional_odds_up_down":"65_35","downside_risk":"HIGH","potential_high":"3.20","potential_low":"1.10","dbr_action":"REVISE"}
|
2026-05-20 to 2026-06-19 Target: $3.20 |
INB-200 ASCO survival update has occurred; focus shifts to market digestion and any FDA-path commentary |
INB-200 clinical update released at ASCO, but FDA-pathway component remains unresolved Catalyst hit. Strong ASCO GBM survival data supports the thesis, while the publication news itself is non-price-setting Catalyst progress. |
|
2026-06-03 12:20:42
Event ID 669
Report 1615
|
NRXP
MODIFIED
|
ACTIVE
ALERT
Parse: PARSED
|
YES_DOWN
Breakout: 34%
DBR: {"expected_direction":"DOWN","directional_odds_up_down":"40_60","downside_risk":"HIGH","potential_high":"4.40","potential_low":"2.60","dbr_action":"REVISE"}
|
2026-06-22 to 2026-08-07 Target: $4.40 |
Summer 2026 FDA ketamine decision remains primary catalyst, but public offering adds dilution despite improving cash runway. |
Primary FDA catalyst still pending; financing changes risk-reward but does not resolve thesis Catalyst progress. Dilutive financing improves runway into FDA review but lowers upside odds and near-term target support. |
|
2026-06-03 12:01:34
Event ID 668
Report 1587
|
LXRX
MODIFIED
|
BROKEN
Parse: PARSED
|
NONE
Breakout: 60%
DBR: {"expected_direction":"PARTIAL_DELAY","directional_odds_up_down":"60_40","downside_risk":"HIGH","potential_high":"3.20","potential_low":"1.20","dbr_action":"REVISE"}
|
2026-06-03 to 2026-12-31 Target: $3.20 |
T1D NDA resubmission and potential year-end FDA approval for sotagliflozin; pilavapadin remains earlier-stage |
News indicated primary catalyst was delayed more than 30 days Catalyst progress. ADA presentations support both programs, but they do not deliver approval or definitive value-bearing outcomes within the original pilavapadin thesis. |
|
2026-06-02 21:14:34
Event ID 667
Report 1653
|
NGNE
NO_CHANGE
|
ACTIVE
Parse: PARSED
|
NONE
Breakout:
DBR: {"expected_direction":"UP","directional_odds_up_down":"60_40","downside_risk":"HIGH","potential_high":"45.00","potential_low":"20.00","dbr_action":"UNCHANGED"}
|
Primary mid-2026 NGN-401 data catalyst remains pending Inducement grants are immaterial to the clinical thesis; Catalyst progress remains unchanged and the key mid-2026 data catalyst has not occurred. |
||
|
2026-06-02 20:02:44
Event ID 666
Report 1615
|
NRXP
MODIFIED
|
ACTIVE
ALERT
Parse: PARSED
|
YES_DOWN
Breakout: 34%
DBR: {"expected_direction":"DOWN","directional_odds_up_down":"35_65","downside_risk":"HIGH","potential_high":"4.40","potential_low":"2.60","dbr_action":"REVISE"}
|
2026-06-22 to 2026-08-07 Target: $4.40 |
Summer 2026 FDA ketamine decision remains the key catalyst, but proposed equity offering raises dilution and financing overhang ahead of the window. |
Primary FDA catalyst still pending; financing news adds overhang but does not resolve or delay it. Catalyst progress: FDA thesis remains intact, but the proposed stock offering increases dilution risk and weakens odds of hitting the prior target. |
|
2026-06-02 13:46:17
Event ID 665
Report 1665
|
MAIA
NO_CHANGE
|
ACTIVE
ALERT
Parse: PARSED
|
YES_UP
Breakout:
DBR: {"expected_direction":"UP","directional_odds_up_down":"62_38","downside_risk":"HIGH","potential_high":"2.60","potential_low":"0.95","dbr_action":"REAFFIRM"}
|
Insider buying and trial-in-progress visibility support sentiment, but the core Phase 3 update catalyst remains pending. Catalyst progress. Insider open-market buying and ASCO trial visibility support confidence, but no thesis-defining Phase 3 efficacy or interim update has occurred. |
||
|
2026-06-02 13:08:09
Event ID 664
Report 1662
|
CRDF
REVISE
|
PARTIALLY_REALIZED
Parse: RAW
|
YES_UP
Breakout:
DBR: {"expected_direction":"UNKNOWN","directional_odds_up_down":"50_50","downside_risk":"UNKNOWN","potential_high":null,"potential_low":null,"dbr_action":"UNKNOWN","parse_warning":"Raw response stored before parsing"}
|
Positive ASCO Phase 2 data released, but full registrational valuation step still depends on webcast interpretation and Phase 3 execution details Catalyst hit. Positive ASCO data support the thesis, but likely confirmatory framing and financing risk temper breakout odds; Catalyst progress. |
||
|
2026-06-02 13:02:16
Event ID 663
Report 1601
|
ONCY
NO_CHANGE
|
ACTIVE
Parse: PARSED
|
NONE
Breakout:
DBR: {"expected_direction":"PARTIAL_DELAY","directional_odds_up_down":"60_40","downside_risk":"HIGH","potential_high":"2.50","potential_low":"0.55","dbr_action":"UNCHANGED"}
|
Interim colorectal data catalyst still pending for year-end 2026 Catalyst progress. Leadership changes may aid execution and partnerships, but they do not alter the year-end 2026 interim data catalyst. |
||
|
2026-06-02 13:01:23
Event ID 662
Report 1625
|
IGC
NO_CHANGE
|
ACTIVE
Parse: PARSED
|
NONE
Breakout:
DBR: {"expected_direction":"PARTIAL_DELAY","directional_odds_up_down":"55_45","downside_risk":"HIGH","potential_high":"0.52","potential_low":"0.24","dbr_action":"REAFFIRM"}
|
Enrollment completion still pending Catalyst progress. Added site and 80% completion update support execution, but enrollment completion and topline analysis have not yet occurred. |
||
|
2026-06-02 12:31:48
Event ID 661
Report 1661
|
ACHV
NO_CHANGE
|
ACTIVE
Parse: PARSED
|
NONE
Breakout:
DBR: {"expected_direction":"PARTIAL_DELAY","directional_odds_up_down":"55_45","downside_risk":"HIGH","potential_high":"9.00","potential_low":"2.75","dbr_action":"REAFFIRM"}
|
FDA decision remains pending; board appointments do not resolve the thesis-defining catalyst. Catalyst progress. Board additions support launch readiness, but the June 20 FDA decision remains the only thesis-defining event. |
||
|
2026-06-02 12:05:49
Event ID 660
Report 1591
|
CADL
MODIFIED
|
PARTIALLY_REALIZED
ALERT
Parse: PARSED
|
YES_UP
Breakout: 72%
DBR: {"expected_direction":"UP","directional_odds_up_down":"75_25","downside_risk":"MEDIUM","potential_high":"11.50","potential_low":"6.50","dbr_action":"REVISE"}
|
2026-06-02 to 2026-06-30 Target: $11.50 |
Peer-reviewed Phase 3 validation and near-term NSCLC Phase 3 initiation |
Phase 3 prostate validation delivered; NSCLC initiation catalyst still pending Catalyst hit. Peer-reviewed Lancet Oncology publication strengthens approval-readiness and re-rating odds, while Catalyst progress continues toward planned NSCLC Phase 3 initiation. |
|
2026-06-02 12:03:15
Event ID 659
Report 1560
|
AEMD
NO_CHANGE
|
PARTIALLY_REALIZED
Parse: PARSED
|
NONE
Breakout:
DBR: {"expected_direction":"PARTIAL_DELAY","directional_odds_up_down":"45_55","downside_risk":"HIGH","potential_high":"3.00","potential_low":"0.60","dbr_action":"REVISE"}
|
Safety progress reached final cohort, efficacy-defining preliminary data still pending Catalyst progress. Earnings-call scheduling does not change the pending oncology data catalyst or materially alter odds within the current June 30 window. |
||
|
2026-06-02 12:03:04
Event ID 658
Report 1622
|
CING
MODIFIED
|
BROKEN
ALERT
Parse: PARSED
|
YES_DOWN
Breakout: 18%
DBR: {"expected_direction":"DOWN","directional_odds_up_down":"20_80","downside_risk":"HIGH","potential_high":"6.50","potential_low":"2.25","dbr_action":"REVISE"}
|
2026-06-02 to 2026-08-31 Target: $6.50 |
CRL received; focus shifts to CMC remediation and NDA resubmission timing |
News indicated primary catalyst was delayed more than 30 days Catalyst hit. FDA issued a CRL, shifting the story to CMC remediation and delaying the approval path beyond the original window. |
|
2026-06-02 11:01:44
Event ID 657
Report 1658
|
IRD
NO_CHANGE
|
ACTIVE
Parse: PARSED
|
NONE
Breakout:
DBR: {"expected_direction":"PARTIAL_DELAY","directional_odds_up_down":"58_42","downside_risk":"HIGH","potential_high":"6.20","potential_low":"3.60","dbr_action":"REAFFIRM"}
|
Science Forum timing confirmed; catalyst still pending Catalyst progress. June 16 forum is confirmed, but no new thesis-defining clinical or regulatory outcome was disclosed. |
||
|
2026-06-01 21:01:36
Event ID 656
Report 1667
|
ZNTL
NO_CHANGE
|
ACTIVE
Parse: PARSED
|
NONE
Breakout:
DBR: {"expected_direction":"UP","directional_odds_up_down":"60_40","downside_risk":"HIGH","potential_high":"5.60","potential_low":"3.20","dbr_action":"UNCHANGED"}
|
Primary post-ASCO interpretation catalyst still pending Inducement grants are immaterial to the ASCO thesis; Catalyst progress. |
||
|
2026-06-01 20:06:43
Event ID 655
Report 1591
|
CADL
NO_CHANGE
|
PARTIALLY_REALIZED
Parse: PARSED
|
NONE
Breakout:
DBR: {"expected_direction":"UP","directional_odds_up_down":"65_35","downside_risk":"HIGH","potential_high":"10.50","potential_low":"6.00","dbr_action":"UNCHANGED"}
|
AUA prostate follow-up data delivered; NSCLC Phase 3 initiation still pending Catalyst hit. Inducement grants are non-core, while the main thesis is partly realized after AUA data with execution catalysts still pending. |
||
|
2026-06-01 20:03:02
Event ID 654
Report 1619
|
KROS
NO_CHANGE
|
ACTIVE
Parse: PARSED
|
NONE
Breakout:
DBR: {"expected_direction":"PARTIAL_DELAY","directional_odds_up_down":"55_45","downside_risk":"HIGH","potential_high":"16.50","potential_low":"9.50","dbr_action":"UNCHANGED"}
|
DMD Phase 2 initiation catalyst still pending Catalyst progress. Conference participation does not confirm the DMD Phase 2 start, so the original execution-based thesis remains pending. |
||
|
2026-06-01 20:02:56
Event ID 653
Report 1662
|
CRDF
NO_CHANGE
|
ACTIVE
Parse: PARSED
|
NONE
Breakout:
DBR: {"expected_direction":"UP","directional_odds_up_down":"70_30","downside_risk":"HIGH","potential_high":"3.60","potential_low":"1.45","dbr_action":"UNCHANGED"}
|
Primary ASCO data catalyst still pending Catalyst progress. Jefferies participation adds visibility, but the thesis still depends on pending ASCO data and webcast within the current window. |
||
|
2026-06-01 13:01:26
Event ID 652
Report 1601
|
ONCY
NO_CHANGE
|
ACTIVE
ALERT
Parse: PARSED
|
YES_UP
Breakout:
DBR: {"expected_direction":"UP","directional_odds_up_down":"60_40","downside_risk":"HIGH","potential_high":"2.50","potential_low":"0.55","dbr_action":"REAFFIRM"}
|
Main interim colorectal data catalyst remains pending for year-end 2026 Catalyst progress. Positive preclinical combination findings support pelareorep’s platform story, but they do not replace the year-end 2026 interim colorectal data catalyst. |
||
|
2026-06-01 12:33:23
Event ID 651
Report 1654
|
ABEO
NO_CHANGE
|
ACTIVE
Parse: PARSED
|
NONE
Breakout:
DBR: {"expected_direction":"UP","directional_odds_up_down":"60_40","downside_risk":"MEDIUM","potential_high":"7.40","potential_low":"4.60","dbr_action":"UNCHANGED"}
|
Primary commercial launch-update catalyst still pending Inducement grants are non-catalytic hiring news; Catalyst progress. they do not change the pending ZEVASKYN launch-update thesis or current window. |
||
|
2026-06-01 12:33:08
Event ID 650
Report 1646
|
PYPD
MODIFIED
|
PARTIALLY_REALIZED
ALERT
Parse: PARSED
|
YES_UP
Breakout: 60%
DBR: {"expected_direction":"UP","directional_odds_up_down":"65_35","downside_risk":"HIGH","potential_high":"6.75","potential_low":"3.40","dbr_action":"REVISE"}
|
2026-06-01 to 2026-07-31 Target: $6.75 |
FDA filing acceptance or refusal-to-file decision following completed D-PLEX100 NDA submission |
NDA submission completion achieved; filing acceptance catalyst still pending Catalyst hit. Catalyst progress. NDA completion advances PYPD into the FDA filing-review stage, shifting the next meaningful catalyst to acceptance or refusal-to-file. |
|
2026-06-01 12:32:51
Event ID 649
Report 1633
|
INAB
MODIFIED
|
PARTIALLY_REALIZED
ALERT
Parse: PARSED
|
YES_UP
Breakout: 46%
DBR: {"expected_direction":"UP","directional_odds_up_down":"68_32","downside_risk":"HIGH","potential_high":"3.40","potential_low":"1.10","dbr_action":"REVISE"}
|
2026-06-01 to 2026-07-15 Target: $3.40 |
ASCO glioblastoma survival update released; focus shifts to market digestion and any FDA-path commentary |
INB-200 survival update delivered, but FDA-path and broader follow-through remain unresolved Catalyst hit. Updated ASCO survival data strengthens the GBM thesis, while Catalyst progress on regulatory-path clarity leaves further upside dependent on follow-through. |
|
2026-06-01 12:07:02
Event ID 648
Report 1589
|
CLRB
MODIFIED
|
PARTIALLY_REALIZED
ALERT
Parse: PARSED
|
YES_UP
Breakout: 60%
DBR: {"expected_direction":"UP","directional_odds_up_down":"65_35","downside_risk":"HIGH","potential_high":"6.50","potential_low":"2.20","dbr_action":"REVISE"}
|
2026-06-01 to 2026-09-30 Target: $6.50 |
U.S. accelerated approval filing progress and mid-2026 CLR 125 data |
Supportive efficacy data released, but main filing catalyst remains pending Catalyst hit. New efficacy data strengthens iopofosine credibility, but focus shifts from EMA submission toward nearer U.S. filing progress and CLR 125 data. |
|
2026-06-01 12:04:39
Event ID 647
Report 1665
|
MAIA
|
UNKNOWN
Parse: RAW
|
NONE
Breakout:
DBR: {"expected_direction":"UNKNOWN","directional_odds_up_down":"50_50","downside_risk":"UNKNOWN","potential_high":null,"potential_low":null,"dbr_action":"UNKNOWN","parse_warning":"Raw response stored before parsing"}
|
Raw response stored before parsing. | ||
|
2026-06-01 12:02:47
Event ID 646
Report 1624
|
ELTX
NO_CHANGE
|
ACTIVE
Parse: PARSED
|
NONE
Breakout:
DBR: {"expected_direction":"UP","directional_odds_up_down":"60_40","downside_risk":"HIGH","potential_high":"19.00","potential_low":"7.50","dbr_action":"UNCHANGED"}
|
Primary Phase 2 DFS catalyst still pending Catalyst progress. Peer-reviewed preclinical platform publication supports biology, but it does not deliver or delay the AMPLIFY-7P Phase 2 DFS readout. |
||
|
2026-06-01 12:02:15
Event ID 645
Report 1621
|
NXTC
MODIFIED
|
PARTIALLY_REALIZED
ALERT
Parse: PARSED
|
YES_UP
Breakout: 58%
DBR: {"expected_direction":"UP","directional_odds_up_down":"65_35","downside_risk":"HIGH","potential_high":"16.50","potential_low":"7.00","dbr_action":"REVISE"}
|
2026-06-01 to 2026-06-30 Target: $16.50 |
ASCO SIM0505 data released with follow-through from initiated gynecologic dose optimization and KOL review |
Positive ASCO SIM0505 data released; follow-through re-rating and optimization execution remain pending Catalyst hit. Positive SIM0505 ASCO data and confirmed dose optimization strengthen upside odds, though financing risk and post-data durability still matter. |
|
2026-06-01 11:32:25
Event ID 644
Report 1664
|
IMRX
MODIFIED
|
BROKEN
ALERT
Parse: PARSED
|
YES_UP
Breakout: 42%
DBR: {"expected_direction":"UP","directional_odds_up_down":"62_38","downside_risk":"HIGH","potential_high":"8.75","potential_low":"4.20","dbr_action":"REVISE"}
|
2026-06-01 to 2026-07-15 Target: $8.75 |
ASCO data readthrough shifts to market digestion and mid-2026 first patient dosing for MAPKeeper 301 |
News indicated primary catalyst was delayed more than 30 days Catalyst hit. Favorable ASCO details strengthen credibility, and Catalyst progress. attention now shifts to Phase 3 first-patient dosing in mid-2026. |
|
2026-06-01 11:31:13
Event ID 643
Report 1580
|
KPTI
MODIFIED
|
BROKEN
Parse: PARSED
|
NONE
Breakout: 55%
DBR: {"expected_direction":"PARTIAL_DELAY","directional_odds_up_down":"55_45","downside_risk":"HIGH","potential_high":"12.50","potential_low":"4.50","dbr_action":"REVISE"}
|
2026-06-01 to 2026-08-15 Target: $12.50 |
SENTRY results presented; focus shifts to XPORT-EC-042 top-line data in mid-2026 |
News indicated primary catalyst was delayed more than 30 days Catalyst hit. SENTRY results are now disclosed, while XPORT-EC-042 remains the next window-relevant catalyst and mixed prior SENTRY readout tempers upside. |
|
2026-06-01 11:01:42
Event ID 642
Report 1597
|
CTXR
NO_CHANGE
|
PARTIALLY_REALIZED
ALERT
Parse: PARSED
|
YES_UP
Breakout:
DBR: {"expected_direction":"UP","directional_odds_up_down":"65_35","downside_risk":"HIGH","potential_high":"2.00","potential_low":"0.45","dbr_action":"REAFFIRM"}
|
Supportive LYMPHIR clinical expansion data released, but core commercial uptake and Mino-Lok catalysts remain pending Catalyst progress. ASCO Phase 1 data supports LYMPHIR expansion upside, but the main window thesis still depends on commercial traction and Mino-Lok progress. |
||
|
2026-05-29 12:22:31
Event ID 641
Report 1618
|
MBRX
MODIFIED
|
PARTIALLY_REALIZED
ALERT
Parse: PARSED
|
YES_UP
Breakout: 45%
DBR: {"expected_direction":"UP","directional_odds_up_down":"58_42","downside_risk":"HIGH","potential_high":"5.75","potential_low":"1.60","dbr_action":"REVISE"}
|
2026-05-13 to 2026-06-30 Target: $5.75 |
June 2026 MIRACLE 45-subject interim unblinding, now modestly de-risked by reinforced non-cardiotoxicity profile and on-track timing. |
Supportive safety evidence released, but primary MIRACLE unblinded efficacy catalyst remains pending Catalyst progress. ASCO safety data and June timing confirmation modestly strengthen the MIRACLE setup, though the thesis-defining unblinded efficacy readout has not occurred. |
|
2026-05-28 20:30:58
Event ID 640
Report 1578
|
TNXP
NO_CHANGE
|
ACTIVE
Parse: PARSED
|
NONE
Breakout:
DBR: {"expected_direction":"UP","directional_odds_up_down":"60_40","downside_risk":"HIGH","potential_high":"25.00","potential_low":"10.00","dbr_action":"UNCHANGED"}
|
Primary Phase 2 initiation catalysts remain pending within window Catalyst progress. Fibromyalgia commercial-support data do not alter pending TNX-4800 and TNX-2900 Phase 2 initiation timing or target odds. |
||
|
2026-05-28 20:03:05
Event ID 639
Report 1658
|
IRD
NO_CHANGE
|
ACTIVE
Parse: PARSED
|
NONE
Breakout:
DBR: {"expected_direction":"UNCERTAIN","directional_odds_up_down":"58_42","downside_risk":"MEDIUM","potential_high":"6.20","potential_low":"3.60","dbr_action":"UNCHANGED"}
|
Primary June 16 science forum catalyst still pending Inducement grants are operational hiring news, not a thesis-defining update; Catalyst progress. |
||
|
2026-05-28 14:35:55
Event ID 638
Report 1632
|
HIND
NO_CHANGE
|
PARTIALLY_REALIZED
ALERT
Parse: PARSED
|
YES_UP
Breakout:
DBR: {"expected_direction":"UP","directional_odds_up_down":"60_40","downside_risk":"HIGH","potential_high":"4.50","potential_low":"1.60","dbr_action":"REAFFIRM"}
|
FDA submissions and orphan-drug filing confirmed, but pivotal design outcome and Phase 3 initiation remain pending Catalyst progress. FDA filings and cash clarity support VT-1953 readiness, but no actual pivotal-design resolution or Phase 3 start was disclosed. |
||
|
2026-05-28 14:15:08
Event ID 637
Report 1603
|
PMN
NO_CHANGE
|
ACTIVE
Parse: PARSED
|
NONE
Breakout:
DBR: {"expected_direction":"PARTIAL_DELAY","directional_odds_up_down":"60_40","downside_risk":"HIGH","potential_high":"19.00","potential_low":"7.00","dbr_action":"REAFFIRM"}
|
Conference participation only; interim data still pending early Q3 2026 Catalyst progress. June conference appearances only reaffirm early Q3 2026 blinded interim timing, without changing the pending PRECISE-AD data catalyst. |
||
|
2026-05-28 12:51:34
Event ID 636
Report 1605
|
ENTX
NO_CHANGE
|
PARTIALLY_REALIZED
ALERT
Parse: PARSED
|
YES_UP
Breakout:
DBR: {"expected_direction":"UP","directional_odds_up_down":"65_35","downside_risk":"HIGH","potential_high":"3.50","potential_low":"0.90","dbr_action":"REAFFIRM"}
|
Supportive new EB613 data and final-tablet selection, but FDA feedback catalyst remains pending Catalyst progress. Late-breaking EB613 presentation supports Phase 3 readiness, but the core FDA feedback catalyst has not yet occurred. |
||
|
2026-05-28 12:31:29
Event ID 635
Report 1587
|
LXRX
NO_CHANGE
|
ACTIVE
Parse: PARSED
|
NONE
Breakout:
DBR: {"expected_direction":"PARTIAL_DELAY","directional_odds_up_down":"60_40","downside_risk":"HIGH","potential_high":"3.50","potential_low":"1.20","dbr_action":"UNCHANGED"}
|
Main catalyst still pending Catalyst progress. Conference presentation only reiterates existing mid-2026 milestones without delivering FDA feedback, approval, or a delay beyond the current window. |
||
|
2026-05-28 11:31:27
Event ID 634
Report 1580
|
KPTI
NO_CHANGE
|
PARTIALLY_REALIZED
Parse: PARSED
|
NONE
Breakout:
DBR: {"expected_direction":"PARTIAL_DELAY","directional_odds_up_down":"55_45","downside_risk":"HIGH","potential_high":"15.33","potential_low":"4.50","dbr_action":"REVISE"}
|
SENTRY top-line outcome disclosed, endometrial catalyst still pending within window Catalyst progress. Conference participation is non-material, while SENTRY data already arrived and the remaining endometrial readout still anchors the June window. |
||
|
2026-05-28 11:02:00
Event ID 633
Report 1615
|
NRXP
NO_CHANGE
|
ACTIVE
Parse: PARSED
|
NONE
Breakout:
DBR: {"expected_direction":"PARTIAL_DELAY","directional_odds_up_down":"55_45","downside_risk":"HIGH","potential_high":"4.80","potential_low":"1.80","dbr_action":"REAFFIRM"}
|
Primary FDA summer 2026 ketamine catalyst remains pending Catalyst progress. Emobot validation supports HOPE’s platform, but it does not alter the pending summer 2026 FDA ketamine decision thesis. |
||
|
2026-05-27 21:05:24
Event ID 632
Report 1553
|
DMAC
MODIFIED
|
BROKEN
Parse: PARSED
|
NONE
Breakout: 55%
DBR: {"expected_direction":"PARTIAL_DELAY","directional_odds_up_down":"55_45","downside_risk":"HIGH","potential_high":"12.33","potential_low":"4.50","dbr_action":"REVISE"}
|
2026-05-27 to 2026-12-31 Target: $12.33 |
ReMEDy2 interim analysis timing shifted to year-end 2026 |
News indicated primary catalyst was delayed more than 30 days Catalyst progress. Conference presentation is non-value-bearing, while recent enrollment guidance pushes the key ReMEDy2 inflection beyond June 2026. |
|
2026-05-27 12:04:46
Event ID 631
Report 1634
|
RNAZ
MODIFIED
|
BROKEN
ALERT
Parse: PARSED
|
YES_UP
Breakout: 34%
DBR: {"expected_direction":"PARTIAL_DELAY","directional_odds_up_down":"60_40","downside_risk":"HIGH","potential_high":"12.50","potential_low":"5.00","dbr_action":"REVISE"}
|
2026-05-27 to 2026-07-31 Target: $12.50 |
Phase 2a initiation confirmed; next catalyst is enrollment, dosing, and early clinical update |
News indicated primary catalyst was delayed more than 30 days Catalyst hit. Phase 2a initiation de-risks activation, but Catalyst progress now shifts focus to enrollment, dosing, and early signals beyond June. |
|
2026-05-27 12:02:35
Event ID 630
Report 1626
|
QTTB
MODIFIED
|
ACTIVE
ALERT
Parse: PARSED
|
YES_DOWN
Breakout: 37%
DBR: {"expected_direction":"PARTIAL_DELAY","directional_odds_up_down":"55_45","downside_risk":"HIGH","potential_high":"11.50","potential_low":"4.50","dbr_action":"REVISE"}
|
2026-06-08 to 2026-07-10 Target: $11.50 |
Mid-2026 SIGNAL-AA Part B topline data remains the core catalyst; financing improves runway but adds dilution. |
Primary clinical readout remains pending; financing changes risk-reward but not catalyst timing. Catalyst progress. Financing extends runway and validates interest, but sizable dilution modestly weakens odds of hitting the prior target before data. |
|
2026-05-27 12:01:32
Event ID 629
Report 1658
|
IRD
NO_CHANGE
|
ACTIVE
Parse: PARSED
|
NONE
Breakout:
DBR: {"expected_direction":"UNCERTAIN","directional_odds_up_down":"58_42","downside_risk":"MEDIUM","potential_high":"6.20","potential_low":"3.60","dbr_action":"UNCHANGED"}
|
Conference presentation confirms visibility but not the June 16 thesis-defining update. Catalyst progress. Jefferies presentation adds investor visibility but does not alter the June 16 forum catalyst, target, or timing. |
||
|
2026-05-27 11:52:09
Event ID 628
Report 1585
|
VSTM
NO_CHANGE
|
ACTIVE
Parse: PARSED
|
NONE
Breakout:
DBR: {"expected_direction":"PARTIAL_DELAY","directional_odds_up_down":"55_45","downside_risk":"HIGH","potential_high":"16.57","potential_low":"4.00","dbr_action":"UNCHANGED"}
|
Clinical data catalyst still pending Catalyst progress. Conference participation adds visibility but does not deliver VS-7375 data or alter the mid-2026 catalyst window. |
||
|
2026-05-27 11:24:29
Event ID 627
Report 1656
|
AUTL
NO_CHANGE
|
ACTIVE
Parse: PARSED
|
NONE
Breakout:
DBR: {"expected_direction":"UP","directional_odds_up_down":"60_40","downside_risk":"HIGH","potential_high":"2.60","potential_low":"1.20","dbr_action":"UNCHANGED"}
|
Primary Q2 commercial catalyst still pending in August 2026 Catalyst progress. Investor conference participation does not change the August commercial-update thesis or materially alter target timing, probability, or direction. |
||
|
2026-05-27 11:04:22
Event ID 626
Report 1578
|
TNXP
NO_CHANGE
|
ACTIVE
Parse: PARSED
|
NONE
Breakout:
DBR: {"expected_direction":"UP","directional_odds_up_down":"60_40","downside_risk":"HIGH","potential_high":"25.00","potential_low":"12.00","dbr_action":"UNCHANGED"}
|
Main Phase 2 initiation catalysts for TNX-4800 and TNX-2900 remain pending Catalyst progress. TNX-1500 publication is supportive, but it does not deliver or displace the original TNX-4800/TNX-2900 Phase 2 initiation thesis. |
||
|
2026-05-27 11:03:43
Event ID 625
Report 1615
|
NRXP
NO_CHANGE
|
ACTIVE
ALERT
Parse: PARSED
|
YES_UP
Breakout:
DBR: {"expected_direction":"UP","directional_odds_up_down":"62_38","downside_risk":"HIGH","potential_high":"4.80","potential_low":"1.80","dbr_action":"REAFFIRM"}
|
Primary FDA summer 2026 catalyst remains pending; commercial network progress is supportive but not thesis-defining. Catalyst progress. HOPE’s Zeta TMS deployment strengthens commercial-readiness sentiment, but the core FDA ketamine approval catalyst has not yet occurred. |
||
|
2026-05-27 11:01:18
Event ID 624
Report 1660
|
AVIR
MODIFIED
|
ACTIVE
ALERT
Parse: PARSED
|
YES_UP
Breakout: 46%
DBR: {"expected_direction":"UP","directional_odds_up_down":"65_35","downside_risk":"HIGH","potential_high":"8.75","potential_low":"3.10","dbr_action":"REVISE"}
|
2026-06-15 to 2026-07-24 Target: $8.75 |
C-BEYOND Phase 3 topline HCV results remain the main catalyst; new EASL DDI data modestly strengthens differentiation narrative. |
Main Phase 3 topline catalyst still pending; EASL data is supportive but not thesis-defining. Catalyst progress. New DDI data supports differentiation and best-in-class positioning, modestly improving odds ahead of still-pending C-BEYOND topline results. |
|
2026-05-27 08:19:51
Event ID 623
Report 1592
|
DTIL
MODIFIED
|
BROKEN
ALERT
Parse: PARSED
|
YES_UP
Breakout: 60%
DBR: {"expected_direction":"UP","directional_odds_up_down":"70_30","downside_risk":"HIGH","potential_high":"12.00","potential_low":"5.00","dbr_action":"REVISE"}
|
2026-05-27 to 2026-12-31 Target: $12.00 |
PBGENE-HBV data hit; next meaningful catalysts are additional ELIMINATE-B updates and DMD initial multi-patient data by year-end 2026 |
News indicated primary catalyst was delayed more than 30 days Catalyst hit. Strong HBV biopsy and biomarker data de-risk the program, but the next major updates now extend beyond July into late 2026. |
|
2026-05-27 08:00:57
Event ID 622
Report 1596
|
ALGS
MODIFIED
|
BROKEN
ALERT
Parse: PARSED
|
YES_UP
Breakout: 45%
DBR: {"expected_direction":"PARTIAL_DELAY","directional_odds_up_down":"60_40","downside_risk":"HIGH","potential_high":"20.00","potential_low":"4.00","dbr_action":"REVISE"}
|
2026-05-27 to 2026-12-31 Target: $20.00 |
Second interim B-SUPREME analysis and follow-through on first interim/partnering validation |
News indicated primary catalyst was delayed more than 30 days Catalyst hit. Positive EASL and prior interim data support the program, but the next meaningful catalyst extends beyond July and lowers near-window upside certainty. |
|
2026-05-26 23:02:09
Event ID 621
Report 1600
|
MNOV
NO_CHANGE
|
ACTIVE
ALERT
Parse: PARSED
|
YES_UP
Breakout:
DBR: {"expected_direction":"UP","directional_odds_up_down":"65_35","downside_risk":"HIGH","potential_high":"3.50","potential_low":"1.00","dbr_action":"REAFFIRM"}
|
MN-001 data catalyst still pending with timing narrowed to Q3 2026 Catalyst progress. LPLV de-risks execution and supports the summer-to-Q3 2026 MN-001 top-line data timeline without delivering results yet. |
||
|
2026-05-26 15:02:41
Event ID 620
Report 1629
|
BRTX
MODIFIED
|
BROKEN
Parse: PARSED
|
NONE
Breakout: 24%
DBR: {"expected_direction":"PARTIAL_DELAY","directional_odds_up_down":"45_55","downside_risk":"HIGH","potential_high":"0.55","potential_low":"0.16","dbr_action":"REVISE"}
|
2027-03-15 to 2027-06-30 Target: $0.55 |
Expected Q2 2027 topline safety and efficacy data from the Phase 2 BRTX-100 lumbar disc disease trial. |
News indicated primary catalyst was delayed more than 30 days Catalyst progress. Dosing completion confirms topline data is expected in Q2 2027, pushing the key catalyst beyond the prior July 2026 window. |
|
2026-05-26 13:08:05
Event ID 619
Report 1601
|
ONCY
|
UNKNOWN
Parse: RAW
|
NONE
Breakout:
DBR: {"expected_direction":"UNKNOWN","directional_odds_up_down":"50_50","downside_risk":"UNKNOWN","potential_high":null,"potential_low":null,"dbr_action":"UNKNOWN","parse_warning":"Raw response stored before parsing"}
|
Raw response stored before parsing. | ||
|
2026-05-26 12:31:24
Event ID 618
Report 1654
|
ABEO
NO_CHANGE
|
ACTIVE
Parse: PARSED
|
NONE
Breakout:
DBR: {"expected_direction":"UP","directional_odds_up_down":"60_40","downside_risk":"HIGH","potential_high":"7.40","potential_low":"4.60","dbr_action":"UNCHANGED"}
|
Main commercial traction catalyst still pending Catalyst progress. Investor conference participation does not deliver new launch data or alter the existing commercial-update thesis window. |
||
|
2026-05-26 12:04:05
Event ID 617
Report 1585
|
VSTM
NO_CHANGE
|
ACTIVE
Parse: PARSED
|
NONE
Breakout:
DBR: {"expected_direction":"UP","directional_odds_up_down":"65_35","downside_risk":"HIGH","potential_high":"16.57","potential_low":"4.00","dbr_action":"UNCHANGED"}
|
Primary VS-7375 data catalyst still pending Catalyst progress. Board appointment supports commercialization and pipeline oversight, but does not alter the pending mid-2026 VS-7375 data catalyst or target window. |
||
|
2026-05-26 12:02:24
Event ID 616
Report 1597
|
CTXR
NO_CHANGE
|
PARTIALLY_REALIZED
ALERT
Parse: PARSED
|
YES_UP
Breakout:
DBR: {"expected_direction":"UP","directional_odds_up_down":"65_35","downside_risk":"HIGH","potential_high":"2.00","potential_low":"0.45","dbr_action":"REAFFIRM"}
|
Commercial traction improved, but core window catalysts remain ongoing Catalyst progress. ASCO presentation and recent revenue/formulary updates support LYMPHIR momentum, but no new thesis-defining approval or Mino-Lok resolution has occurred. |
||
|
2026-05-26 12:02:00
Event ID 615
Report 1639
|
GANX
MODIFIED
|
PARTIALLY_REALIZED
ALERT
Parse: PARSED
|
YES_UP
Breakout: 34%
DBR: {"expected_direction":"UP","directional_odds_up_down":"65_35","downside_risk":"HIGH","potential_high":"3.10","potential_low":"1.45","dbr_action":"REVISE"}
|
2026-05-26 to 2026-06-20 Target: $3.10 |
Positive Phase 1b interim data presented; focus shifts to near-term FDA/IND path clarification and Phase 2 execution details |
Supportive Phase 1b data delivered, but FDA/IND path update remains unresolved Catalyst hit. Positive Phase 1b data supports the thesis, but missing FDA-path clarity shifts the next meaningful catalyst into the near-term follow-up window. |
|
2026-05-26 11:57:54
Event ID 614
Report 1644
|
OSTX
NO_CHANGE
|
ACTIVE
Parse: PARSED
|
NONE
Breakout:
DBR: {"expected_direction":"UNCERTAIN","directional_odds_up_down":"55_45","downside_risk":"HIGH","potential_high":"3.40","potential_low":"1.20","dbr_action":"UNCHANGED"}
|
FDA Pre-BLA outcome still pending Conference attendance is non-value-bearing scheduling news; Catalyst progress. the FDA Pre-BLA disclosure remains the key unresolved driver within the current window. |
||
|
2026-05-26 11:17:05
Event ID 613
Report 1652
|
NGEN
MODIFIED
|
PARTIALLY_REALIZED
ALERT
Parse: PARSED
|
YES_UP
Breakout: 46%
DBR: {"expected_direction":"UP","directional_odds_up_down":"65_35","downside_risk":"MEDIUM","potential_high":"5.75","potential_low":"2.60","dbr_action":"REVISE"}
|
2026-05-26 to 2026-06-30 Target: $5.75 |
Positive blinded gait analyses released; focus shifts to subacute update and RESTORE Phase 3 initiation readiness |
One predicted 2Q clinical catalyst occurred positively, while subacute update and RESTORE initiation remain pending Catalyst hit. Positive blinded gait data and fresh funding improve confidence, though dilution and remaining execution risk cap upside. |
|
2026-05-26 11:03:02
Event ID 612
Report 1578
|
TNXP
NO_CHANGE
|
ACTIVE
Parse: PARSED
|
NONE
Breakout:
DBR: {"expected_direction":"UP","directional_odds_up_down":"60_40","downside_risk":"HIGH","potential_high":"25.00","potential_low":"10.00","dbr_action":"UNCHANGED"}
|
Phase 2 initiation catalysts remain pending within window Catalyst progress. Fibromyalgia market-support data do not alter the pending Phase 2 initiation thesis or current August 2026 catalyst window. |
||
|
2026-05-26 11:02:35
Event ID 611
Report 1569
|
CGEM
NO_CHANGE
|
PARTIALLY_REALIZED
ALERT
Parse: PARSED
|
YES_UP
Breakout:
DBR: {"expected_direction":"UP","directional_odds_up_down":"65_35","downside_risk":"HIGH","potential_high":"29.50","potential_low":"8.50","dbr_action":"REAFFIRM"}
|
Initial CLN-978 autoimmune data disclosed, broader 2026 catalyst set still pending Catalyst hit. Promising initial CLN-978 autoimmune data supports the thesis, but major later-2026 milestones including additional data and zipalertinib approval remain pending. |
||
|
2026-05-26 11:02:02
Event ID 610
Report 1593
|
RNAC
MODIFIED
|
BROKEN
ALERT
Parse: PARSED
|
YES_UP
Breakout: 55%
DBR: {"expected_direction":"PARTIAL_DELAY","directional_odds_up_down":"60_40","downside_risk":"HIGH","potential_high":"18.00","potential_low":"4.50","dbr_action":"REVISE"}
|
2026-05-26 to 2027-03-31 Target: $18.00 |
Phase 3 AURORA topline data in myasthenia gravis expected in 1Q27, supported by strengthened non-dilutive funding. |
News indicated primary catalyst was delayed more than 30 days Catalyst progress. Non-dilutive financing reduces funding risk, but AURORA topline shifted beyond the old window into 1Q27. |
|
2026-05-26 08:10:48
Event ID 609
Report 1592
|
DTIL
NO_CHANGE
|
PARTIALLY_REALIZED
Parse: PARSED
|
NONE
Breakout:
DBR: {"expected_direction":"UP","directional_odds_up_down":"65_35","downside_risk":"HIGH","potential_high":"15.00","potential_low":"4.50","dbr_action":"UNCHANGED"}
|
DMD trial startup progressed and HBV presentation occurred, but main value-defining human data thesis is still pending Catalyst progress. Breaking news is unrelated to DTIL, while DTIL’s core HBV and DMD catalysts remain pending within the current window. |
||
|
2026-05-26 08:10:41
Event ID 608
Report 1592
|
DTIL
NO_CHANGE
|
PARTIALLY_REALIZED
Parse: PARSED
|
NONE
Breakout:
DBR: {"expected_direction":"PARTIAL_DELAY","directional_odds_up_down":"60_40","downside_risk":"HIGH","potential_high":"15.00","potential_low":"4.50","dbr_action":"REAFFIRM"}
|
DMD site activation and enrollment began, but key HBV follow-on data and multi-patient DMD data remain pending Catalyst progress. Breaking news is unrelated to DTIL, while DTIL has advanced DMD startup but not yet delivered the thesis-defining clinical readouts. |
||
|
2026-05-22 18:04:55
Event ID 607
Report 1592
|
DTIL
MODIFIED
|
BROKEN
Parse: PARSED
|
NONE
Breakout: 60%
DBR: {"expected_direction":"PARTIAL_DELAY","directional_odds_up_down":"60_40","downside_risk":"HIGH","potential_high":"15.00","potential_low":"4.50","dbr_action":"REVISE"}
|
2026-05-22 to 2026-12-31 Target: $15.00 |
Additional PBGENE-HBV clinical biomarker and biopsy data in 1H 2026 and initial multi-patient PBGENE-DMD data by year-end 2026. |
News indicated primary catalyst was delayed more than 30 days Catalyst progress: DMD enrollment has begun, but the main value-driving data catalyst extends beyond July while unrelated financing news does not affect DTIL directly. |
|
2026-05-22 13:01:15
Event ID 606
Report 1601
|
ONCY
NO_CHANGE
|
PARTIALLY_REALIZED
ALERT
Parse: PARSED
|
YES_UP
Breakout:
DBR: {"expected_direction":"UP","directional_odds_up_down":"65_35","downside_risk":"HIGH","potential_high":"2.50","potential_low":"0.55","dbr_action":"REAFFIRM"}
|
Supportive colorectal durability and mechanistic evidence emerged, but year-end randomized interim data remains pending Catalyst progress. ASCO presentation and recent mCRC durability data strengthen sentiment, but the main year-end randomized interim-data catalyst has not occurred. |
||
|
2026-05-22 11:32:18
Event ID 605
Report 1599
|
BCTX
MODIFIED
|
BROKEN
ALERT
Parse: PARSED
|
YES_UP
Breakout: 60%
DBR: {"expected_direction":"PARTIAL_DELAY","directional_odds_up_down":"60_40","downside_risk":"HIGH","potential_high":"12.00","potential_low":"2.50","dbr_action":"REVISE"}
|
2026-05-22 to 2026-12-31 Target: $12.00 |
Phase 3 topline data timing shifted to 2026; interim readout remains primary catalyst |
News indicated primary catalyst was delayed more than 30 days Catalyst progress. Positive ASCO data supports the program, but topline Phase 3 results now appear later than the original July window. |
|
2026-05-22 08:00:32
Event ID 604
Report 1652
|
NGEN
MODIFIED
|
PARTIALLY_REALIZED
ALERT
Parse: PARSED
|
YES_DOWN
Breakout: 34%
DBR: {"expected_direction":"PARTIAL_DELAY","directional_odds_up_down":"45_55","downside_risk":"HIGH","potential_high":"5.25","potential_low":"2.35","dbr_action":"REVISE"}
|
2026-06-08 to 2026-06-30 Target: $5.25 |
2Q 2026 CONNECT SCI gait analyses and subacute update, now supported by strengthened funding for RESTORE Phase 3 execution |
Funding overhang resolved but core 2Q clinical catalyst still pending Catalyst progress. Financing materially improves Phase 3 readiness but near-term dilution and warrant overhang reduce odds of hitting the prior target this month. |
|
2026-05-21 21:11:18
Event ID 603
Report 1656
|
AUTL
NO_CHANGE
|
ACTIVE
Parse: PARSED
|
NONE
Breakout:
DBR: {"expected_direction":"PARTIAL_DELAY","directional_odds_up_down":"55_45","downside_risk":"HIGH","potential_high":"2.60","potential_low":"1.25","dbr_action":"REAFFIRM"}
|
Primary commercial Q2 catalyst still pending Catalyst progress. ASCO presentation adds supportive clinical visibility, but the August commercial update remains the thesis-defining catalyst. |
||
|
2026-05-21 21:03:19
Event ID 602
Report 1618
|
MBRX
NO_CHANGE
|
ACTIVE
Parse: PARSED
|
NONE
Breakout:
DBR: {"expected_direction":"UP","directional_odds_up_down":"60_40","downside_risk":"HIGH","potential_high":"5.50","potential_low":"1.80","dbr_action":"REAFFIRM"}
|
Primary MIRACLE interim unblinding remains pending in June 2026 Catalyst progress. ASCO abstract acceptance supports Annamycin safety narrative, but the thesis-defining MIRACLE unblinding has not occurred and timing remains unchanged. |
||
|
2026-05-21 20:06:47
Event ID 601
Report 1642
|
INO
MODIFIED
|
BROKEN
ALERT
Parse: PARSED
|
YES_UP
Breakout: 38%
DBR: {"expected_direction":"UP","directional_odds_up_down":"60_40","downside_risk":"HIGH","potential_high":"1.60","potential_low":"0.95","dbr_action":"REVISE"}
|
2026-05-21 to 2026-06-30 Target: $1.60 |
ApolloBio VGX-3100 China regulatory-filing progress and any follow-up INO-3107 FDA-review updates |
News indicated primary catalyst was delayed more than 30 days Catalyst progress. ApolloBio’s positive Phase 3 result supports platform credibility and milestone potential, but it does not replace the still-pending INO-3107 review catalyst. |
|
2026-05-21 20:02:43
Event ID 600
Report 1652
|
NGEN
MODIFIED
|
ACTIVE
ALERT
Parse: PARSED
|
YES_DOWN
Breakout: 28%
DBR: {"expected_direction":"DOWN","directional_odds_up_down":"35_65","downside_risk":"HIGH","potential_high":"5.25","potential_low":"2.90","dbr_action":"REVISE"}
|
2026-06-08 to 2026-06-30 Target: $5.25 |
2Q 2026 CONNECT SCI gait analyses and subacute tetraplegia update, now offset by near-term financing dilution overhang |
Primary 2Q clinical catalyst remains pending; financing adds overhang but does not resolve or break it Catalyst progress. Proposed equity and warrant financing improves execution runway but likely pressures shares and lowers odds of reaching the prior target within June. |
|
2026-05-21 13:16:43
Event ID 599
Report 1595
|
BFRI
NO_CHANGE
|
ACTIVE
Parse: PARSED
|
NONE
Breakout:
DBR: {"expected_direction":"UNCERTAIN","directional_odds_up_down":"55_45","downside_risk":"HIGH","potential_high":"1.50","potential_low":"0.55","dbr_action":"UNCHANGED"}
|
September 2026 sBCC PDUFA remains pending Catalyst progress. Investor conference participation does not change the September 2026 FDA catalyst, target window, or thesis odds materially. |
||
|
2026-05-21 12:48:12
Event ID 598
Report 1592
|
DTIL
NO_CHANGE
|
ACTIVE
Parse: PARSED
|
NONE
Breakout:
DBR: {"expected_direction":"UP","directional_odds_up_down":"65_35","downside_risk":"HIGH","potential_high":"15.00","potential_low":"4.50","dbr_action":"UNCHANGED"}
|
HBV data release is pending; DMD initial multi-patient data remains future Catalyst progress. Breaking news is unrelated, while HBV data are only scheduled for May 27 and the core clinical catalyst has not yet occurred. |
||
|
2026-05-21 12:02:27
Event ID 597
Report 1560
|
AEMD
NO_CHANGE
|
PARTIALLY_REALIZED
Parse: PARSED
|
NONE
Breakout:
DBR: {"expected_direction":"PARTIAL_DELAY","directional_odds_up_down":"55_45","downside_risk":"HIGH","potential_high":"30.00","potential_low":"0.60","dbr_action":"REVISE"}
|
Oncology trial advanced with positive safety review, but preliminary efficacy-defining data remains pending. Catalyst progress. Ebola preparedness is non-core, while oncology trial advancement supports but does not complete the original data catalyst thesis. |
||
|
2026-05-21 12:01:57
Event ID 596
Report 1592
|
DTIL
NO_CHANGE
|
PARTIALLY_REALIZED
ALERT
Parse: PARSED
|
YES_UP
Breakout:
DBR: {"expected_direction":"UP","directional_odds_up_down":"65_35","downside_risk":"HIGH","potential_high":"15.00","potential_low":"4.50","dbr_action":"REAFFIRM"}
|
DMD trial enrollment started and new HBV data scheduled for May 27 Catalyst progress. New HBV data are imminent and DMD trial startup supports the thesis without yet fully delivering the thesis-defining outcome. |
||
|
2026-05-21 11:20:14
Event ID 595
Report 1592
|
DTIL
MODIFIED
|
PARTIALLY_REALIZED
ALERT
Parse: PARSED
|
YES_UP
Breakout: 55%
DBR: {"expected_direction":"UP","directional_odds_up_down":"60_40","downside_risk":"HIGH","potential_high":"10.00","potential_low":"5.50","dbr_action":"REVISE"}
|
2026-05-21 to 2026-05-27 Target: $10.00 |
Late-breaking PBGENE-HBV biopsy and clinical data release at EASL 2026 |
DMD startup progressed, while HBV data catalyst is now specifically scheduled but not yet disclosed Catalyst progress. New HBV data are imminent on May 27, replacing the broader window and modestly improving near-term upside visibility. |
|
2026-05-20 13:07:58
Event ID 594
Report 1483
|
JAGX
MODIFIED
|
ACTIVE
Parse: PARSED
|
NONE
Breakout: 35%
DBR: {"expected_direction":"PARTIAL_DELAY","directional_odds_up_down":"45_55","downside_risk":"HIGH","potential_high":"4.50","potential_low":"1.50","dbr_action":"REVISE"}
|
2026-05-20 to 2027-07-31 Target: $4.50 |
MVID pivotal trial completion and NDA filing progress for crofelemer |
Main crofelemer approval catalyst still pending beyond prior window Catalyst progress: webcast and trial-extension updates support crofelemer development, but NDA timing shifted to mid-2027, pushing the main catalyst beyond May 2026. |
|
2026-05-20 13:02:04
Event ID 593
Report 1570
|
CDXS
MODIFIED
|
PARTIALLY_REALIZED
ALERT
Parse: PARSED
|
YES_UP
Breakout: 60%
DBR: {"expected_direction":"UP","directional_odds_up_down":"60_40","downside_risk":"HIGH","potential_high":"3.20","potential_low":"1.40","dbr_action":"REVISE"}
|
2026-02-15 to 2026-06-15 Target: $3.20 |
Axolabs ECO Synthesis evaluation remains pending; new TIDES data strengthens platform credibility |
Supportive platform data released, but Axolabs adoption outcome remains pending Catalyst progress. New ECO Synthesis data supports the thesis, but Catalyst hit. has not occurred because Axolabs adoption remains unresolved. |
|
2026-05-20 12:37:55
Event ID 592
Report 1553
|
DMAC
MODIFIED
|
ACTIVE
ALERT
Parse: PARSED
|
YES_UP
Breakout: 58%
DBR: {"expected_direction":"PARTIAL_DELAY","directional_odds_up_down":"60_40","downside_risk":"HIGH","potential_high":"12.33","potential_low":"4.50","dbr_action":"REVISE"}
|
2026-05-20 to 2026-12-31 Target: $12.33 |
ReMEDy2 interim analysis completion and DSMB recommendation for DM199 in acute ischemic stroke. |
Enrollment milestone reached, but trial results and interim analysis remain pending. Catalyst progress. 75% enrollment supports execution, but the key interim analysis now falls after June, extending timing and slightly lowering near-term target odds. |
|
2026-05-20 12:31:33
Event ID 591
Report 1646
|
PYPD
NO_CHANGE
|
ACTIVE
Parse: PARSED
|
NONE
Breakout:
DBR: {"expected_direction":"UP","directional_odds_up_down":"58_42","downside_risk":"HIGH","potential_high":"6.75","potential_low":"3.40","dbr_action":"UNCHANGED"}
|
NDA completion catalyst still pending Catalyst progress. Investor conference participation does not change the pending NDA-completion catalyst, timing window, or probability in a material way. |
||
|
2026-05-19 23:16:28
Event ID 590
Report 1625
|
IGC
NO_CHANGE
|
ACTIVE
Parse: PARSED
|
NONE
Breakout:
DBR: {"expected_direction":"PARTIAL_DELAY","directional_odds_up_down":"55_45","downside_risk":"HIGH","potential_high":"0.52","potential_low":"0.24","dbr_action":"REAFFIRM"}
|
Enrollment completion still pending; 80% status reiterated Catalyst progress. Q1 results reiterate CALMA at 80% enrollment, while financing flexibility helps execution but does not change the mid-2026 enrollment catalyst. |
||
|
2026-05-19 22:13:36
Event ID 589
Report 1583
|
SNES
NO_CHANGE
|
PARTIALLY_REALIZED
Parse: PARSED
|
NONE
Breakout:
DBR: {"expected_direction":"PARTIAL_DELAY","directional_odds_up_down":"60_40","downside_risk":"HIGH","potential_high":"3.50","potential_low":"1.30","dbr_action":"UNCHANGED"}
|
CEO transition completed and commercial traction improved; approval catalyst still pending Catalyst progress. Investor conference participation is non-value-bearing, while recent CEO appointment and Q1 traction support but do not complete the approvals-driven thesis. |
||
|
2026-05-19 20:31:50
Event ID 588
Report 1620
|
CVKD
NO_CHANGE
|
PARTIALLY_REALIZED
Parse: PARSED
|
NONE
Breakout:
DBR: {"expected_direction":"PARTIAL_DELAY","directional_odds_up_down":"55_45","downside_risk":"HIGH","potential_high":"8.50","potential_low":"3.50","dbr_action":"REAFFIRM"}
|
Phase 3 path clarified, but protocol finalization and start timing still pending Catalyst progress: investor conference participation adds visibility, but no new Phase 3 protocol finalization or start-timing disclosure was provided. |
||
|
2026-05-19 13:15:51
Event ID 587
Report 1483
|
JAGX
MODIFIED
|
ACTIVE
Parse: PARSED
|
NONE
Breakout: 45%
DBR: {"expected_direction":"PARTIAL_DELAY","directional_odds_up_down":"55_45","downside_risk":"EXTREME","potential_high":"5.25","potential_low":"1.50","dbr_action":"REVISE"}
|
2026-05-19 to 2027-07-31 Target: $5.25 |
MVID pivotal trial completion and potential NDA filing timing shifted to mid-2027 |
trial progressing but main regulatory catalyst remains pending Catalyst progress. Extension-phase entry supports crofelemer development, but NDA timing moved beyond May 2026 and listing/financial risks temper target confidence. |
|
2026-05-19 12:02:52
Event ID 586
Report 1592
|
DTIL
NO_CHANGE
|
PARTIALLY_REALIZED
Parse: PARSED
|
NONE
Breakout:
DBR: {"expected_direction":"PARTIAL_DELAY","directional_odds_up_down":"60_40","downside_risk":"HIGH","potential_high":"15.00","potential_low":"4.50","dbr_action":"REAFFIRM"}
|
DMD trial startup advanced, but key HBV and multi-patient DMD data remain pending Catalyst progress. Breaking news is unrelated, while DTIL has advanced DMD enrollment but has not yet delivered the thesis-defining clinical data. |
||
|
2026-05-19 12:02:45
Event ID 585
Report 1592
|
DTIL
NO_CHANGE
|
PARTIALLY_REALIZED
Parse: PARSED
|
NONE
Breakout:
DBR: {"expected_direction":"PARTIAL_DELAY","directional_odds_up_down":"60_40","downside_risk":"HIGH","potential_high":"15.00","potential_low":"4.50","dbr_action":"UNCHANGED"}
|
DMD trial startup progressed, but key HBV and multi-patient DMD data remain pending Non-DTIL breaking news is irrelevant; Catalyst progress. DTIL’s thesis still depends on pending HBV data and later DMD clinical readouts. |
||
|
2026-05-19 11:26:57
Event ID 584
Report 1598
|
ATHE
NO_CHANGE
|
ACTIVE
ALERT
Parse: PARSED
|
YES_UP
Breakout:
DBR: {"expected_direction":"UP","directional_odds_up_down":"70_30","downside_risk":"MEDIUM","potential_high":"7.00","potential_low":"2.80","dbr_action":"REAFFIRM"}
|
End-of-Phase-2 meeting still pending mid-2026 Catalyst progress. Conference data and FDA-track confirmation support Phase 3 readiness, but the End-of-Phase-2 meeting catalyst has not yet occurred. |
||
|
2026-05-19 11:03:06
Event ID 583
Report 1617
|
KRRO
MODIFIED
|
REALIZED
ALERT
Parse: PARSED
|
YES_UP
Breakout: 46%
DBR: {"expected_direction":"UP","directional_odds_up_down":"65_35","downside_risk":"HIGH","potential_high":"21.00","potential_low":"10.00","dbr_action":"REVISE"}
|
2026-05-19 to 2026-06-30 Target: $21.00 |
AATD development-candidate nomination occurred with KRRO-111 selection, shifting focus to market digestion and follow-on preclinical detail. |
AATD development-candidate nomination occurred Catalyst hit. KRRO-111 nomination validates execution and platform progress, modestly improving odds of a sentiment-driven re-rating within the existing window. |
|
2026-05-19 11:01:35
Event ID 582
Report 1569
|
CGEM
MODIFIED
|
PARTIALLY_REALIZED
ALERT
Parse: PARSED
|
YES_UP
Breakout: 78%
DBR: {"expected_direction":"UP","directional_odds_up_down":"72_28","downside_risk":"MEDIUM","potential_high":"29.50","potential_low":"8.50","dbr_action":"REVISE"}
|
2026-03-01 to 2026-12-31 Target: $29.50 |
CLN-978 initial clinical data at EULAR and ongoing zipalertinib/CLN-049 clinical-regulatory progress |
Supportive CLN-978 abstract and CLN-049 orphan designation strengthen thesis, but key data readouts remain pending Catalyst progress. FDA orphan designation and upcoming CLN-978 data modestly strengthen 2026 upside odds without yet delivering the core readouts. |
|
2026-05-18 21:01:20
Event ID 581
Report 1569
|
CGEM
MODIFIED
|
PARTIALLY_REALIZED
ALERT
Parse: PARSED
|
YES_UP
Breakout: 55%
DBR: {"expected_direction":"UP","directional_odds_up_down":"65_35","downside_risk":"MEDIUM","potential_high":"18.00","potential_low":"9.00","dbr_action":"REVISE"}
|
2026-05-18 to 2026-06-06 Target: $18.00 |
Initial CLN-978 autoimmune clinical data presentation at EULAR 2026 |
Initial abstract shows supportive safety, B-cell depletion, and early activity; full catalyst data presentation remains pending Catalyst progress. Early CLN-978 abstract is encouraging, but full EULAR data on June 6 will determine whether upside expands materially. |
|
2026-05-18 20:32:24
Event ID 580
Report 1592
|
DTIL
MODIFIED
|
PARTIALLY_REALIZED
Parse: PARSED
|
NONE
Breakout: 55%
DBR: {"expected_direction":"UP","directional_odds_up_down":"55_45","downside_risk":"HIGH","potential_high":"10.00","potential_low":"5.00","dbr_action":"REVISE"}
|
2026-05-18 to 2026-06-30 Target: $10.00 |
HBV clinical biomarker and biopsy data; DMD enrollment startup progress |
DMD trial startup advanced, but core HBV data catalyst remains pending Catalyst progress. Conference news is irrelevant to DTIL, while DMD enrollment started and HBV data remain the key near-term driver. |